Adamas Healthcare Fund team hails from diversified backgrounds and has know-how ranging from successful investment experience to strong industry track record.
Dov Malnik Founder
Dov Malnik founded Adamas Healthcare Fund in 2014. Mr. Malnik has been investing in the global financial markets for over 15 years, focusing on event driven investments and short selling, based on deep research in highly specialized sectors.
Earlier in his career, from 2006, Mr. Malnik was a senior private banker at UBP Bank in Switzerland, managing a portfolio of over $250M of HNW clients, with focus on opportunistic equity trading. He started his career at CIBC World Markets as an equity trader.
In 2002 Mr. Malnik received his B.S. in Finance and International Business from the Carlson School Of Management at the University of Minnesota. Mr. Malnik was an accomplished professional swimmer. He was the Israeli national champion and record holder, and represented Israel in multiple world championships.
Ofir Levi, PhD Scientific Research
Dr. Ofir Levi is leading the research at Adamas Healthcare Fund since its inception in 2014. The research team conducts deep scientific analysis of publicly traded pharmaceutical and biotechnology companies. Prior to Adamas Healthcare Fund, Dr. Levi was the founder and CEO at Bioassociate Ltd, an expertise-based consulting, research and analysis company focused on the pharmaceutical, biotechnology and life science sectors. As the CEO at Bioassociate’s, Dr. Levi led team of experts rom both scientific nd financial fields who work closely together on harnessing company’s potential and placing it firmly on the path for success. Dr. Levi together with the Tel Aviv stock exchange management team incorporated the guidelines or sponsored analysis for biotech companies at the TASE.
Until 2011 Dr. Levi was the CEO of Radmor Biocap LLC , which advised and invested in seed and early stage companies in the area of pharmaceutical development, clinical diagnostics and medical devices. Led by Dr. Levi, Radmor had signed several license agreements with leading universities around the world for novel technologies, and established companies developing these technologies.
In 2006 Dr. Levi completed his PhD studies in Prof. Daniel Michaelson’s neurobiology lab at Tel-Aviv University. During the 4 years of his PhD studies, Dr. Levi led a research group of several students in both in-house research and several international collaborations. Dr. Levi’s PhD thesis focused on neurogenesis processes in Alzheimer’s Disease.
Dr. Ofir Levi is the Author of several published articles in leading scientific journals.
Gal Ophir, PhD Scientific Research
Dr. Gal Ophir is leading the research at Adamas Healthcare Fund since its inception in 2014. Dr. Ophir and his team performs deep scientific analysis of publicly traded pharmaceutical and biotechnology companies, and advise the fund’s manager regarding investment decisions in accordance with the portfolio management team.
Prior to joining Adamas Healthcare Fund, Dr. Ophir was a founding partner and head of scientific research at Bioassociate Ltd, an expertise-based consulting, research and analysis company focused on the pharmaceutical, biotechnology and life science sectors.
Until 2010 Dr. Ophir was the Co-Founder and Co-CEO at EZQuant Ltd, a company that developed software solutions for the bio-medical research field. EZQuant’s activity was eventually licensed to DNR bio-imaging.
In 2006 Dr. Ophir completed his PhD studies in Prof. Daniel Michaelson’s neurobiology lab at Tel-Aviv University. During the 5 years of PhD studies, Dr. Ophir led a research group of several students in both in-house research and several international collaborations. Dr. Ophir’s PhD thesis focused on neuro-inflammatory processes in Alzheimer’s Disease and head injury.
In advance of his PhD studies, Dr. Ophir was a researcher at D-Pharm Ltd., a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. Dr. Ophir led a research team in one of D-Pharm’s R&D labs.
Roi Raz Strategy and Trading
Roi Raz is the portfolio strategist for Adamas Healthcare Fund since its inception in 2014. Mr. Raz has been trading in global financial markets for 13 years, out of which more than 7 dedicated to managing portfolios investing in the biotechnology and pharmaceutical sectors.
Prior to Adama Healthcare, from 2013 Mr. Raz was managing the global event-driven biopharma portfolio of Mascall Management, a Swiss investment advisory firm specializing in long/short equity investment based on intensive bottom-up research.
From 2007 until 2013 Mr. Raz was an equity and derivatives trader with Barak Capital, a subsidiary of the Delek Group (TASE: DLEKG) which manages over $1Bn in proprietary trading capital. Mr. Raz started his career as an equity/index options market maker, later playing an important role in founding the delta 1 desk of the firm. From 2011 Mr. Raz was managing a long/short equity portfolio focusing on pharma and chemicals.
In 2007 Mr. Raz received his BA (Hons) in Business Administration and LL.B in Law from IDC Herlzlyia. During his studies Mr. Raz was accepted onto the Zell Entrepreneurship Program, an academic incubator program for outstanding business students. In addition Mr. Raz participated in several healthcare specialized academic programs including Medical Neuroscience (Duke University) and Healthcare Innovation (Tel Aviv University).